IP Verse

Abbvie competitive analysis

Latest oppositions filed by Abbvie

Explore patent oppositions filed by Abbvie against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 9, 2025

Patent Number	Title	Applicant	Opposition Date
Get instant updates on new opposition filings by the company
EP3819007	Dosing Regimen For Anti-Bcma Agents	AMGEN	Apr 9, 2025
EP4058148	Dosing Regimen For Anti-Bcma Agents	AMGEN	Dec 13, 2024
EP3177645	Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of Cancer	LINDHOFER	Nov 17, 2021
EP3616720	Pharmaceutical Composition For Cancer Treatment	OSAKA UNIVERSITY	Nov 16, 2021
EP3153526	Antibodies Against Human Cd39 And Use Thereof For Inhibiting T Regulatory Cells Activity	INSERM INSTITUT NATIONAL DE LA SANT ET DE LA RECHERCHE MDICALE	Jun 21, 2021
EP3219328	Human Anti-Il-23 Antibodies, Compositions, Method And Uses	JANSSEN BIOTECH	Mar 17, 2021
EP2978446	Methods And Agents For Treating Alzheimer'S Disease	THE GENERAL HOSPITAL	Dec 4, 2020
EP2780375	Binding Molecules For Bcma And Cd3	AMGEN	Mar 6, 2020
EP2654789	Antibodies Against Human Cd39 And Use Thereof	INSERM INSTITUT NATIONAL DE LA SANT ET DE LA RECHERCHE MDICALE	Feb 15, 2019
EP2530091	Anti-Dll3 Antibody	CHUGAI SEIYAKU KABUSHIKI KAISHA	Jan 4, 2019

Latest patents of Abbvie opposed by its competitors

Explore Abbvie's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 9, 2025

Patent Number	Grant Date	Title	Total Oppositions
EP3377110	Jan 6, 2021	Nanoparticles Based On Optionally Alkoxylated Poly(Alkyl Cyanoacrylates) Having A Defined Degree Of Polymerization	1
EP2691134	Oct 7, 2020	Improved Shroud Deployment In Automatic Injection Devices	1
EP3213750	Aug 12, 2020	Combination Of Two Antivirals For Treating Hepatitis C	1
EP2897611	Jul 24, 2019	Methods For Treating Hepatitis C	1
EP2968302	Feb 13, 2019	Combination Of Direct Acting Antiviral Agents And Ribavirin For Treating Hcv Patients	1
EP2954892	Jul 18, 2018	Solid Compositions	1
EP2957307	Jul 18, 2018	Automatic Injection Device	1
EP2258346	Sep 27, 2017	Solid Pharmaceutical Dosage Form Comprising An Hiv Protease Inhibitor Solid Dispersion	1
EP2643322	Aug 30, 2017	Salts And Crystalline Forms Of An Apoptosis-Inducing Agent	1
EP2506716	May 17, 2017	Novel Tricyclic Compounds	1

Latest publications and patents of Abbvie New

Explore the latest publications and patents granted to Abbvie, showcasing their recent innovations and technological advancements.

Last updated on: Oct 7, 2025

Publication Number	Publication Date	Title	Legal Status
Get instant update for new patents of Abbvie
EP4212515	Jul 19, 2023	Quinazolinones As Parp14 Inhibitors	Intended To Grant
EP3986887	Apr 27, 2022	Targeted Protein Degradation Of Parp14 For Use In Therapy	Request For Examination Was Made
EP3377110	Jan 6, 2021	Nanoparticles Based On Optionally Alkoxylated Poly(Alkyl Cyanoacrylates) Having A Defined Degree Of Polymerization	Revoked
EP2691134	Oct 7, 2020	Improved Shroud Deployment In Automatic Injection Devices	Patent Maintained As Amended
EP3213750	Aug 12, 2020	Combination Of Two Antivirals For Treating Hepatitis C	Granted And Under Opposition
EP2897611	Jul 24, 2019	Methods For Treating Hepatitis C	Granted And Under Opposition
EP2968302	Feb 13, 2019	Combination Of Direct Acting Antiviral Agents And Ribavirin For Treating Hcv Patients	Revoked
EP2957307	Jul 18, 2018	Automatic Injection Device	Revoked
EP2954892	Jul 18, 2018	Solid Compositions	Revoked
EP3091017	Jan 17, 2018	Apoptosis-Inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases	No Opposition Filed Within Time Limit

Latest PTAB cases involving Abbvie

Discover the latest PTAB cases involving Abbvie, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 13, 2025

Proceeding Number	Filing Date	Petitioner	Respondent	Status
Get alerts for PTAB Cases involving Abbvie
PGR2022-00040	May 12, 2022	NEURODERM	ABBVIE	Final Written Decision
IPR2018-00156	Nov 6, 2017	SANDOZ	ABBVIE BIOTECHNOLOGY	Institution Denied
IPR2018-00002	Oct 2, 2017	SANDOZ	ABBVIE BIOTECHNOLOGY	Institution Denied
IPR2017-02105	Sep 14, 2017	SANDOZ	ABBVIE BIOTECHNOLOGY	Terminated-Settled
IPR2017-02106	Sep 14, 2017	SANDOZ	ABBVIE BIOTECHNOLOGY	Terminated-Settled
IPR2017-01987	Aug 21, 2017	SANDOZ	ABBVIE BIOTECHNOLOGY	Institution Denied
IPR2017-01988	Aug 21, 2017	SANDOZ	ABBVIE BIOTECHNOLOGY	Institution Denied
IPR2017-01823	Jul 20, 2017	SANDOZ	ABBVIE BIOTECHNOLOGY	Institution Denied
IPR2017-01824	Jul 20, 2017	SANDOZ	ABBVIE BIOTECHNOLOGY	Institution Denied
IPR2017-01008	Mar 2, 2017	COHERUS BIOSCIENCES	ABBVIE BIOTECHNOLOGY	Institution Denied

Peer Comparison New

IP litigation analysis comparing Abbvie with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 9, 2025

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
ABBVIE	10	9	-	1
AMGEN	8	138	8	11
AMGEN RESEARCH MUNICH	-	30	-	-
GENERICS UK	212	-	-	-